Comparative guide · 5 min read

DHEA vs Pregnenolone — which hormone precursor (if any) actually has evidence?

Updated 2026-05-21 · Reviewed by SupplementScore editors · No sponsorships

Read this first. These are hormones, not vitamins. Both are restricted or prescription-only in most countries outside the US (banned outright in Canada, the UK, Australia and elsewhere). Self-supplementing hormone precursors without baseline labs, monitoring, and a clinician's involvement is not what the evidence supports. The signals reviewed below come from carefully monitored trials with specific patient populations — not healthy adults taking gummies for anti-aging.

Both are upstream steroid hormones produced by the adrenal cortex and gonads. DHEA (dehydroepiandrosterone) has the larger and better-characterised trial literature — modest signals in adrenal insufficiency, certain depression subtypes, vaginal atrophy (where it's a prescription drug in many countries), and some lupus contexts. Pregnenolone has a smaller and less-replicated literature; the cleanest current signals are in schizophrenia adjunct trials and a handful of cognitive-aging studies. For most healthy adults, neither has a clean evidence base for the "hormone optimisation" marketing they're sold under.

Quick verdict

Use caseBetter choiceWhy
Healthy adults seeking anti-agingNeitherNo clean trial signal; real downstream sex-steroid effects in both directions.
Documented adrenal insufficiency (low DHEA-S)DHEA (under endocrinology supervision)The clinical context with the best DHEA evidence; clinician-led not OTC.
Post-menopausal vulvovaginal atrophyDHEA intravaginal (Rx)Prasterone (FDA-approved 2016) has clean trial evidence; OTC oral DHEA is a different question.
Schizophrenia adjunct (with antipsychotic)Pregnenolone (research-context)The best-known pregnenolone signal — adjunct to antipsychotics, not standalone.
Mild depressionDHEA (small case)Two short RCTs show mood-symptom benefit; far weaker evidence than first-line treatments.
Bone density / sarcopeniaNeither (modest DHEA signal)DHEA has small bone signals in older women; effect smaller than weight-bearing exercise + protein + creatine.
Memory / cognitive aging (healthy adults)NeitherTrial data are inconsistent; the marketing far outruns the evidence.

How they compare on the things that matter

Mechanism — different points in the steroidogenic pathway

Pregnenolone is the master steroid precursor — every steroid hormone in the body is downstream of it, made from cholesterol in the mitochondria of steroid-producing cells. From there the pathway forks: one branch goes to progesterone and the mineralocorticoid/glucocorticoid arm (aldosterone, cortisol), the other to DHEA and the sex-steroid arm (testosterone, estradiol).

DHEA sits further downstream, on the sex-steroid arm. It's the most abundant circulating steroid in humans and falls roughly 80% from age 25 to 75 — the age-decline that drives the "supplement to restore" marketing. In practice, exogenous DHEA can convert peripherally to both testosterone and estradiol, with the conversion ratio differing by sex and tissue. That dual conversion is why DHEA in women raises androgens (acne, hirsutism) and in men raises estrogens (gynecomastia, suppressed testicular function at higher doses).

Evidence base by clinical endpoint

Practical rule. Don't self-supplement either one for "anti-aging" or "hormone balance." If you suspect a real endocrine problem (fatigue + low libido + weight changes + low DHEA-S on labs), the right path is endocrinology evaluation — not OTC hormones. The trial-supported uses of these compounds are clinician-led and population-specific.

Dose and form

For DHEA: trial doses for adrenal insufficiency are 25–50 mg/day in women, lower in men. Higher doses (100–200 mg/day) have been used in depression and SLE trials and produce stronger downstream sex-steroid effects. OTC dosing is highly variable; product-to-product label accuracy has been poor in past testing (independent assays have found wide variance from label).

For pregnenolone: trial doses run 30–500 mg/day. The schizophrenia adjunct trials used 200–500 mg/day. OTC products typically come in 10–50 mg capsules; the bigger trial doses require multiple capsules per day.

Safety

DHEA produces real androgenic effects in women (acne, hirsutism, voice deepening at sustained higher doses), real estrogenic effects in men (gynecomastia, testicular suppression at sustained higher doses), and may worsen hormone-sensitive cancers (breast, prostate, ovarian, uterine). It also raises insulin resistance markers in some users and may worsen sleep apnoea. Lipid changes have been reported.

Pregnenolone has been less well-characterised for adverse effects, but mechanism predicts the same downstream sex-steroid issues as DHEA at the upper dose range. Mood effects (anxiety, irritability) have been reported anecdotally and in some trials.

Both are banned by WADA — competitive athletes should not use them. Both should be avoided in pregnancy, lactation, hormone-sensitive cancers, and in users on aromatase inhibitors or anti-androgens.

What the price difference buys you

OTC DHEA runs $0.10–0.25/day; OTC pregnenolone $0.10–0.30/day. Cost is not the bottleneck. The bottleneck is the lack of clean indications outside specific clinical scenarios where a prescriber should be involved.

Who should skip each

DHEA should be avoided in: hormone-sensitive cancers (breast, prostate, ovarian, uterine), pregnancy and lactation, untreated BPH, active polycystic ovary syndrome with hyperandrogenism, and in athletes subject to anti-doping rules.

Pregnenolone should be avoided in: the same hormone-sensitive cancer contexts, pregnancy and lactation, untreated hormone-driven endocrine conditions, and athletes subject to anti-doping rules.

What we'd actually buy

For a healthy adult with general anti-aging interest: neither. Both fail the basic "clean signal in healthy adults" test. Creatine, omega-3, vitamin D, and adequate protein have far better risk-adjusted evidence for aging well.

For someone with a documented endocrine indication (Addison's disease, prescribed for vulvovaginal atrophy, schizophrenia adjunct under psychiatric care): the relevant pharmaceutical product at clinician-monitored doses, not the OTC supplement aisle.

Sources

Read more: